Research programme: therapeutic antibodies - Epitomics/InNexus

Drug Profile

Research programme: therapeutic antibodies - Epitomics/InNexus

Latest Information Update: 02 Dec 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Epitomics; InNexus Biotechnology
  • Class Monoclonal antibodies
  • Mechanism of Action Apoptosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Myocardial infarction; Stroke

Most Recent Events

  • 22 Mar 2006 DXL™ Technology is available for licensing or partnering worldwide (
  • 12 Jan 2005 Preclinical trials in Myocardial infarction in USA (unspecified route)
  • 12 Jan 2005 Preclinical trials in Stroke in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top